全部产品 / DC11512
CAT. NO. DC11512
Acrizanib
产品概要
Acrizanib 是一种VEGFR-2抑制剂,对BaF3-KDR的IC50为17.4 nM。
仅供科研使用。研究结果取决于实验条件,不构成产品性能保证。
产品身份与规格
| 目录号 | DC11512 |
|---|---|
| 产品名称 | Acrizanib |
| CAS | 1229453-99-9 |
| 分子式 | C20H18F3N7O2 |
| 分子量 | 445.3978 |
| 纯度 | >98% |
| SMILES | FC(C1=C([H])C(=NN1C([H])([H])[H])N([H])C(N1C([H])=C([H])C2C([H])=C(C([H])=C([H])C1=2)OC1C([H])=C(C([H])([H])N([H])C([H])([H])[H])N=C([H])N=1)=O)(F)F |
来源列示的产品规格;具体要求以批次 COA 为准。
原始研究与产品文件
详细实验条件、性能数据和参考文献请参见英文原始资料。COA、SDS及批次文件请向客服索取。
英文原始产品资料原文参考文献
Rat ocular PK studies with Acrizanib shows a distinctly different profile from that observed with compound 25. While prolonged exposure is once again evident in the PEC, the AUC ratio to the level of Acrizanib in plasma is markedly increased (>21000-fold higher exposure in the PEC than plasma on day 11). Furthermore, unlike 25, Acrizanib also afford much improved retina to plasma AUC exposure ratio after 10 days of dosing (598× for Acrizanib vs 0.8× for 25)[1].
